Pricing Log in Create free account
Friday 16 October 2026 Export ALEC’s income statement to Excel — free account

Alector, Inc.

ALEC Healthcare Biotechnology

Alector, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $21.0 million, down 79.1% from fiscal 2024. In the quarter to June 2026, revenue fell 57.8%, EPS grew 30.0%, free cash flow grew 30.2% and total debt rose 3.27%, each against the same quarter a year earlier.

1.84 0.07 −3.66%
Market cap
$213.3M
P/E
0.0×
Fwd P/E
−1.9×
Dividend yield
—
F-score
1/9
Altman Z
−5.15
Beneish M
n/a
Dividend safety
n/a
Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Insider Decisions trades per month

Total sells 1.02
Totals in millions of $.
Dec 25 Mar 26 Jun 26 Sep 26
Buy — — — — — — — — — — — —
Sell — 5 — 1 5 1 — 3 — — 3 —
Insider Ownership 25.95%

Capital & Financial Ratios $m

Market Cap 213.27
Revenue 13.86
Net Income (117.85)
Free Cash Flow (158.39)
Net Debt (162.95)
Current Ratio 5.26 (at or above 1.5: strong)
Debt/Equity (0.99) (negative: negative equity)
P/E ratio 0.00
Fwd P/E (1.91) (negative: loss-making)
P/S ratio 14.76 (above 10: high)
P/B ratio 0.00
Past 5Y EPS Growth —
This Y EPS Growth 72.53% (at or above 15%: strong)
Next Y EPS Growth (118.98%) (below 0%: weak)
Next Y revenue growth 10.33% (at or above 10%: strong)
Next 5Y EPS Growth 20.29% (at or above 15%: strong)

Green and red mark values outside typical ranges. How we judge →

Valuation vs history

EV/Sales, ten years
EV/Sales is 3.6×, against a ten-year median of 1.0×; over the ten years it ranged from −4.1× in 2025 to 88.0× in 2021.
P/S against its own 10 years 64.27%
10-year low 10-year high
EV/Sales against its own 10 years 38.83%
10-year low 10-year high

Dividends

Payout Ratio —
Annual Dividend Rate —
Annual Dividend Yield —
total individual payouts
2025 Powerpack
2024 Powerpack
2023 Powerpack
2022 Powerpack
2021 Powerpack
2020 Powerpack
2019 Powerpack
2018 Powerpack
predictions special payouts not included in total or ratios

Assets vs Liabilities $m

2023 2024 2025 Q'26
Cash 549 413 256 173
Receivables — — — —
Inventory — — — —
Other — — — —
566 425 266 180
2023 2024 2025 Q'26
Payables 4 2 2 2
ST’ Debt — — 0 10
Other 39 49 11 —
178 125 70 34

Compound Annual Growth %

10y 5y 3y
Sales — (0.05%) (46.00%)
Cash Flow — 0.00% 0.00%
Earnings — 0.00% 0.00%
Book Value — (35.17%) (47.72%)

Revenue $m

Mar Jun Sep Dec Year
’26 1 3 — — —
’25 4 8 3 6 21
’24 16 15 15 54 101
’23 17 56 9 15 97
’22 24 80 15 14 134
’21 4 7 182 14 207
’20 7 3 6 5 21
Fiscal quarters ending in the months shown.

Operating Cash Flow $m

Mar Jun Sep Dec Year
’26 (50) (34) — — —
’25 (61) (49) (33) (42) (184)
’24 (61) (63) (51) (55) (230)
’23 (49) (43) (47) (46) (184)
’22 135 (57) (49) (49) (20)
’21 (53) (45) 445 (49) 299
’20 (32) (46) (41) (48) (167)
Fiscal quarters ending in the months shown.

Free Cash Flow $m

Mar Jun Sep Dec Year
’26 (50) (34) — — —
’25 (61) (49) (33) (42) (184)
’24 (62) (63) (51) (55) (231)
’23 (50) (44) (46) (46) (187)
’22 134 (58) (51) (50) (24)
’21 (54) (45) 444 (50) 295
’20 (36) (46) (41) (48) (172)
Fiscal quarters ending in the months shown.

EPS $

Mar Jun Sep Dec Year
’26 (0.21) (0.21) — — —
’25 (0.41) (0.30) (0.34) (0.34) (1.39)
’24 (0.38) (0.40) (0.43) (0.02) (1.23)
’23 (0.55) 0.02 (0.53) (0.49) (1.56)
’22 (0.54) 0.12 (0.56) (0.63) (1.62)
’21 (0.66) (0.69) 1.49 (0.68) (0.45)
’20 (0.53) (0.58) (0.67) (0.66) (2.45)
Fiscal quarters ending in the months shown.

Target Price Range

Analyst price targets

Recommendation Rating

2.6
1Buy 2 3Hold 4 5Sell

Ten years at a glance Fiscal years to December

Group Line 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 Trend 2026e 2027e 2028e
Price, $
Price, $ Low — — — 13.64 9.12 14.66 6.85 3.66 1.68 0.87

Analyst estimates 2026–2028

Powerpack
High — — — 27.00 35.93 43.32 21.26 9.86 8.90 3.40
People
People Employees — — 78 121 171 208 273 244 238 103
Revenue/emp, $m 0.00 0.00 0.35 0.18 0.12 1.00 0.49 0.40 0.42 0.20
Income, $m
Income, $m Revenue 0 4 28 21 21 207 134 97 101 21
Gross margin, % 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00
EBT (15) (32) (52) (105) (190) (36) (130) (125) (119) (143)
EBT margin, % (3,632.21) (869.61) (188.78) (496.65) (901.64) (17.54) (97.33) (128.97) (118.26) (678.36)
Net income (15) (32) (52) (105) (190) (36) (133) (130) (119) (143)
Depreciation 0 1 1 6 8 10 7 (6) (6) 3
Per share, $
Per share, $ Revenue 0.06 0.41 2.45 0.34 0.27 2.58 1.62 1.16 1.04 0.20
Earnings (2.11) (3.55) (4.62) (1.71) (2.45) (0.45) (1.62) (1.56) (1.23) (1.39)
Cash flow (1.81) (1.94) 11.28 (1.61) (2.14) 3.71 (0.25) (2.20) (2.38) (1.79)
Capex (0.31) (0.09) (0.17) (0.25) (0.06) (0.04) (0.05) (0.03) (0.01) 0.00
Free cash flow (2.13) (2.03) 11.11 (1.86) (2.21) 3.67 (0.30) (2.23) (2.39) (1.79)
Book value 0.00 2.78 10.01 3.15 3.44 3.74 2.60 1.60 1.31 0.30
Shares, m 7 9 11 62 78 80 82 84 97 103
Valuation, ×
Valuation, × P/E 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
P/S 7.67 7.67 7.67 50.13 55.76 8.02 5.62 6.89 1.82 7.64
P/B 0.00 0.00 0.00 5.46 4.40 5.52 3.50 4.99 1.44 5.24
EV/Sales (2.82) (2.82) (2.82) 35.75 38.60 4.70 0.61 1.65 (2.12) (4.07)
EV/FCF (0.62) (0.62) (0.62) (6.62) (4.74) 3.29 (3.31) (0.86) 0.92 0.47
Cash, $m
Cash, $m Operating cash flow (13) (18) 127 (99) (167) 299 (20) (184) (230) (184)
Capex (2) (1) (2) (15) (5) (3) (4) (2) (1) 0
Free cash flow (15) (19) 126 (115) (172) 295 (24) (187) (231) (184)
Balance, $m
Balance, $m Working capital 50 206 245 295 353 610 633 388 300 197
Total debt — — — 48 51 48 43 — 9 10
Net debt (51) (32) (290) (305) (362) (688) (670) (549) (404) (246)
Shareholders’ equity — 25 113 195 268 301 214 134 127 31
Returns, %
Returns, % ROA (12.80) (27.52) (19.19) (28.86) (41.80) (5.58) (16.64) (18.50) (21.84) (37.54)
ROIC 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
ROE 39.28 84.43 69.93 (216.52) (82.30) (12.79) (51.75) (74.81) (91.24) (181.56)
Negative figures in brackets.

All 10 years →

Fiscal years to Dec 2025 · latest quarter Jun 2026

Charts ten years each

Alector, Inc. vs peers in Biotechnology (Q) = latest quarter vs a year earlier

Company Market cap P/E Fwd P/E Revenue growth (Q) EPS growth (Q) FCF growth (Q) Gross margin (Q) EBIT margin (Q) Compare
LXEO Lexeo Therapeutics, Inc. $226.6M — (loss-making) — (loss-making) — n/m +35.58% (above 0%: growing) 0.00% 0.00% Compare
PLX Protalix BioTherapeutics, Inc. $217.5M 11.4× 10.2× +27.07% (above 0%: growing) +2,280.95% (above 0%: growing) −94.09% (below 0%: shrinking) 60.99% 23.48% Compare
CAMP CAMP4 Therapeutics Corporation $216.5M — (loss-making) — (loss-making) +18.84% (above 0%: growing) n/m −23.90% (below 0%: shrinking) 100.00% (752.11%) Compare
PYXS Pyxis Oncology, Inc. $215.3M — (loss-making) — (loss-making) — n/m −5.46% (below 0%: shrinking) 100.00% 0.00% Compare
EVMN Evommune Inc. $215.2M — (loss-making) — (loss-making) — n/m +21.78% (above 0%: growing) 100.00% 0.00% Compare
MGNX MacroGenics, Inc. $214.7M — (loss-making) — (loss-making) +377.97% (above 0%: growing) n/m +12.88% (above 0%: growing) 100.00% (42.19%) Compare
ALEC Alector, Inc. $213.3M — (loss-making) — (loss-making) −57.84% (below 0%: shrinking) n/m +30.19% (above 0%: growing) 100.00% (734.73%)
ZNTL Zentalis Pharmaceuticals, Inc. $212.1M — (loss-making) — (loss-making) — n/m −9.06% (below 0%: shrinking) 100.00% 0.00% Compare
ADCT ADC Therapeutics SA $190.2M — (loss-making) — (loss-making) +2.17% (above 0%: growing) n/m +50.98% (above 0%: growing) 87.80% (132.03%) Compare
Median of peers $215.2M — — +22.96% — +3.71% 100.00% 0.00%

All 614 Biotechnology stocks →

Alector, Inc. (ALEC) key facts

  • Concern: Alector, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $21.0 million, down 79.1% from fiscal 2024.
  • Concern: Alector, Inc. reported a net loss of $142.9 million, or a loss of $1.39 per share, for fiscal 2025.
  • Alector, Inc. (ALEC) is a Biotechnology company in the Healthcare sector, listed on Nasdaq.
  • As of October 16, 2026, ALEC traded at $1.84, a market capitalization of $213.3 million.
  • Trailing earnings are negative, so a P/E ratio is not meaningful; the stock trades at 14.8× sales.
  • Return on equity was −181.6% and debt-to-equity -0.99.
  • Its Piotroski F-score is 1 out of 9 and its Altman Z-score is −5.15 (distress zone) for fiscal 2025.

Source: company filings (standardised) and stockrow calculations.

Alector, Inc. (ALEC) Latest News

No news at this impact. Lower the threshold for more.
stockrow.com/ALEC · Data as of Jun 30, 2026 · For information only; not investment advice. · © 2026 stockrow.com